Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2484-2496

  Abravanel, Daniel L ^a,b   Belka, George K ^a,b   Pan, Tien Chi ^a,b   Pant, Dhruv K ^a,b   Collins, Meredith A ^a,b   Sterner, Christopher J ^a,b   Chodosh, Lewis A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NOTCH RECEPTOR; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR HES 1; ERBB2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; HUMAN; HUMAN CELL; META ANALYSIS (TOPIC); MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR RECURRENCE; UPREGULATION; AGED; ANIMAL; BREAST NEOPLASMS; CANCER TRANSPLANTATION; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL CULTURE; XENOGRAFT;

AGED; ANIMALS; BREAST NEOPLASMS; DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; META-ANALYSIS AS TOPIC; MICE; MICE, NUDE; MICE, TRANSGENIC; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84930405158     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74883     Document Type: Article

References (88)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2): 69-90.
2. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996;41(2): 177-185.
3. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14(10): 2738-2746.
4. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999;91(1): 80-85.
5. Weiss RB, et al. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: A study by the Cancer and Leukemia Group B. J Clin Oncol. 2003;21(9): 1825-1835.
6. Braun S, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8): 793-802.
7. Janni W, et al. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - A European pooled analysis. Clin Cancer Res. 2011;17(9): 2967-2976.
8. Mathiesen RR, et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res. 2012;14(4): R117.
9. Pantel K, et al. Differential expression of proliferation- Associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993;85(17): 1419-1424.
10. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8(5): 329-340.
11. D'Cruz CM, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 2001;7(2): 235-239.
12. Gunther EJ, et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 2002;16(3): 283-292.
13. Moody SE, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2002;2(6): 451-461.
14. Gunther EJ, et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 2003;17(4): 488-501.
15. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell. 2004;6(6): 577-586.
16. Moody SE, et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005;8(3): 197-209.
17. Hurley J, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol. 2006;24(12): 1831-1838.
18. Mittendorf EA, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15(23): 7381-7388.
19. Nakamura R, Yamamoto N, Onai Y, Watanabe Y, Kawana H, Miyazaki M. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients. Breast Cancer. 2013;20(4): 336-341.
20. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol. 2012;9(1): 16-32.
21. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-Amplified breast cancer: Mechanisms and clinical implications. Crit Rev Oncog. 2012;17(1): 1-16.
22. Robinson DR, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011;17(12): 1646-1651.
23. Jhappan C, et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev. 1992;6(3): 345-355.
24. Gallahan D, et al. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res. 1996;56(8): 1775.
25. Raafat A, Bargo S, Anver MR, Callahan R. Mammary development and tumorigenesis in mice expressing a truncated human Notch4/ Int3 intracellular domain (h-Int3sh). Oncogene. 2004;23(58): 9401-9407.
26. Kiaris H, et al. Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol. 2004;165(2): 695-705.
27. Hu C, Diévart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol. 2006;168(3): 973-990.
28. Martz CA, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014;7(357): Ra121.
29. Farnie G, et al. Novel cell culture technique for primary ductal carcinoma in situ: Role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst. 2007;99(8): 616-627.
30. Reedijk M, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65(18): 8530-8537.
31. Barretina J, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391): 603-607.
32. Wertheim GB, et al. The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis. Proc Natl Acad Sci U S A. 2009;106(37): 15855-15860.
33. Mazzone M, et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A. 2010;107(11): 5012-5017.
34. Lewis HD, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol. 2007;14(2): 209-219.
35. Tammam J, et al. Down-regulation of the Notch pathway mediated by a ?-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol. 2009;158(5): 1183-1195.
36. Palomero T, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10): 1203-1210.
37. Osipo C, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a ?-secretase inhibitor. Oncogene. 2008;27(37): 5019-5032.
38. Pandya K, et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer. 2011;105(6): 796-806.
39. Komurov K, et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol Syst Biol. 2012;8: 596.
40. Nakayama K, Satoh T, Igari A, Kageyama R, Nishida E. FGF induces oscillations of Hes1 expression and Ras/ERK activation. Curr Biol. 2008;18(8): R332-R334.
41. Sato T, et al. FRS2a regulates Erk levels to control a self-renewal target Hes1 and proliferation of FGF-responsive neural stem/progenitor cells. Stem Cells. 2010;28(9): 1661-1673.
42. Sweeney C, et al. Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem. 2001;276(25): 22685-22698.
43. Amin DN, Perkins AS, Stern DF. Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene. 2004;23(7): 1428-1438.
44. Kobayashi T, Kageyama R. Hes1 regulates embryonic stem cell differentiation by suppressing Notch signaling. Genes Cells. 2010;15(7): 689-698.
45. Lamar E, et al. Nrarp is a novel intracellular component of the Notch signaling pathway. Genes Dev. 2001;15(15): 1885-1899.
46. Weng AP, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol. 2003;23(2): 655-664.
47. Maillard I, et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood. 2004;104(6): 1696-1702.
48. Kato H, et al. Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives. Development. 1997;124(20): 4133-4141.
49. Han H, et al. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int Immunol. 2002;14(6): 637-645.
50. Yamaguchi N, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of Erb- B2-negative human breast cancer cells. Cancer Res. 2008;68(6): 1881-1888.
51. Watters JW, et al. De novo discovery of a ?-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res. 2009;69(23): 8949-8957.
52. Efferson CL, et al. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res. 2010;70(6): 2476-2484.
53. Kondratyev M, et al. ?-Secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. 2012;31(1): 93-103.
54. Chang HY, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005;102(10): 3738-3743.
55. Chanrion M, et al. A gene expression signature that can predict the recurrence of tamoxifen- treated primary breast cancer. Clin Cancer Res. 2008;14(6): 1744-1752.
56. Chin K, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10(6): 529-541.
57. Desmedt C, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13(11): 3207-3214.
58. Hess KR, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24(26): 4236-4244.
59. Esserman LJ, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012;132(3): 1049-1062.
60. Ivshina AV, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006;66(21): 10292-10301.
61. Ma XJ, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5(6): 607-616.
62. Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403): 346-352.
63. Minn AJ, et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A. 2007;104(16): 6740-6745.
64. Oh DS, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006;24(11): 1656-1664.
65. Pawitan Y, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: Derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7(6): R953-R964.
66. Sabatier R, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat. 2011;126(2): 407-420.
67. Schmidt M, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68(13): 5405-5413.
68. Sotiriou C, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4): 262-272.
69. Wang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet. 2005;365(9460): 671-679.
70. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2): 249-264.
71. Morita S, Kojima T, Kitamura T. Plat-E: An efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7(12): 1063-1066.
72. Student. The probable error of a mean. Biometrika. 1908;6(1): 1-25.
73. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18(1): 50-60.
74. Shapiro S, Wilk M. An analysis of variance test for normality (complete samples). Biometrika. 1965;52(3): 591-611.
75. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50(272): 1096-1121.
76. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc. 1961;56(293): 52-64.
77. Greenhouse SW, Geisser S. On methods in the analysis of profile data. Psychometrika. 1959;24(2): 95-112.
78. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282): 457-481.
79. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4): 719-748.
80. Baldi P, Long AD. A Bayesian framework for the analysis of microarray expression data: Regularized t-test and statistical inferences of gene changes. Bioinformatics. 2001;17(6): 509-519.
81. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B Stat Methodol. 1995;57(1): 289-300.
82. Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-Analysis of gene expression microarray datasets. PLoS Med. 2008;5(9): E184.
83. Cochran W. The combination of estimates from different experiments. Biometrics. 1954;10(1): 101-129.
84. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin Trials. 1986;7(3): 177-188.
85. Whitehead A, Whitehead J. A general parametric approach to the meta-Analysis of randomized clinical trials. Stat Med. 1991;10(11): 1665-1677.
86. Rubin MA, Chinnaiyan AM. Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer. Lab Invest. 2006;86(11): 1099-1102.
87. Popovici V, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010;12(1): R5.
88. Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8): 1160-1167.